LB Pharmaceuticals Inc Common Stock
LBRX · NASDAQ
9/30/2025 | 6/30/2025 | 9/30/2024 | 6/30/2024 | |
|---|---|---|---|---|
| Revenue | $0 | – | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | – | $0 | $0 |
| Gross Profit | -$0 | – | -$0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $2 | – | $11 | $24 |
| G&A Expenses | $0 | – | $0 | $2 |
| SG&A Expenses | $3 | – | $5 | $2 |
| Sales & Mktg Exp. | $0 | – | $0 | $0 |
| Other Operating Expenses | $0 | – | $0 | $0 |
| Operating Expenses | $5 | – | $16 | $27 |
| Operating Income | -$5 | – | -$16 | -$27 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $2 | – | $2 | -$1 |
| Pre-Tax Income | -$4 | – | -$14 | -$28 |
| Tax Expense | $0 | – | $0 | $0 |
| Net Income | -$4 | – | -$14 | -$28 |
| % Margin | – | – | – | – |
| EPS | -0.14 | – | -0.63 | -7.82 |
| % Growth | – | – | 91.9% | – |
| EPS Diluted | -0.14 | – | -0.63 | -7.82 |
| Weighted Avg Shares Out | 25 | – | 22 | 4 |
| Weighted Avg Shares Out Dil | 25 | – | 22 | 4 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | – | $0 | $0 |
| Interest Expense | $0 | – | $0 | $0 |
| Depreciation & Amortization | $0 | – | $0 | $0 |
| EBITDA | -$3 | – | -$14 | -$27 |
| % Margin | – | – | – | – |